{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-225323","form_type":"8-K","ticker":"SNSE","cik":"0001829802","company_name":"Sensei Biotherapeutics, Inc.","filed_at":"2026-05-15T11:35:06+00:00","discovered_at":"2026-05-15T11:40:00.249340+00:00","generated_at":"2026-05-15T11:40:46.573745+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Sensei Biotherapeutics Q1 net loss $170.2M; cash $202.8M; PIKTOR trial advances","bullets":["Net loss of $170.2M ($131.45 per share) vs $6.9M loss a year ago, driven by $133.0M acquired IPR&D charge from Faeth acquisition.","Cash, cash equivalents and marketable securities $202.8M, up from $21.2M at Dec 31, 2025, after $200M private placement in February.","First patient dosed in Phase 1b/2 trial of PIKTOR for HR+/HER2- advanced breast cancer; Phase 2 endometrial cancer topline data expected H2 2026.","R&D expenses $18.0M (vs $3.7M) and G&A $19.7M (vs $3.5M) both increased due to Faeth acquisition and one-time costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-225323","json":"https://secwatch.observer/filing/0001193125-26-225323.json","markdown":"https://secwatch.observer/filing/0001193125-26-225323.md","text":"https://secwatch.observer/filing/0001193125-26-225323.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526225323/0001193125-26-225323-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526225323/d125741d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T11:40:46.573745+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8160775298f56a5befeb182b1155b23091a684f6","claim":"Sensei Biotherapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income Net loss was $170.2 million, or $131.45 per basic and diluted share.","evidence_excerpt":"On May 15, 2026, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829802/000119312526225323/0001193125-26-225323-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2026"},{"label":"Net income","value":"Net loss was $170.2 million, or $131.45 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}